Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Tantalizing Market for Stroke Devices

This article was originally published in Start Up

Executive Summary

A potentially enormous market without therapeutic options is attracting a lot of new technology developesr and venture capital to stroke. But the opportunity for clot-busting approaches is limited and getting enough patients for clinical trials is tough. In a market full of unknowns, one thing is certain: the ultimate goal of any stroke therapy is to avoid neurological deficit.

You may also be interested in...



Interventional Neuroradiology's Growing Pains

Neuroendovascular devices for treating hemorrhagic and ischemic stroke, while investigational, are gaining attention because of technology advances, intriguing anecdotal evidence of efficacy in a field in which previous drug therapies haven't worked, and positive but controversial emerging clinical data. Companies are pursuing neuro applications of endovascular devices, but despite lots of noise, clinical challenges and uncertain market potential restrain many from investing heavily in the field.

Interventional Neuroradiology's Growing Pains

Neuroendovascular devices for treating hemorrhagic and ischemic stroke, while investigational, are gaining attention because of technology advances, intriguing anecdotal evidence of efficacy in a field in which previous drug therapies haven't worked, and positive but controversial emerging clinical data. Companies are pursuing neuro applications of endovascular devices, but despite lots of noise, clinical challenges and uncertain market potential restrain many from investing heavily in the field.

Shades of BENESTENT in the Aneurysm World

UK investigators' recent decision to call an early halt to enrollment in a major study comparing neurosurgical clipping to endovascular coil treatment of ruptured cerebral aneurysms may signal a significant change of practice habits in a critical area of neurology. The findings, if they're as good as they appear to be, could do to surgical clipping and endovascular coils what the BENESTENT trials of the early 1990s did to promote stenting over balloon angioplasty in patients with coronary artery disease.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

MT037012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel